AI
By
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Aspira Women’s Health and Cleveland Clinic’s New AI Alliance Rewrite the Rules for Women’s Diagnostics Across Ovarian Cancer and Beyond?
Key Highlights A Strategic Alliance Built for Scale Aspira Women’s Health and Cleveland Clinic have entered a comprehensive…
Will Big Pharma’s Billion-Dollar AI Investments Reshape the US$2 Trillion Pharmaceutical Industry Faster Than the Next Blockbuster Drug?
Key Highlights The AI Investment Race Has Officially Begun Artificial intelligence has rapidly evolved from an experimental technology…
Can Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
